ArticleCureus2025
Variability in Clinical Response to Steroids in Granulomatous Mastitis: A Report of Two Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic granulomatous mastitis (IGM) is a rare, benign, chronic inflammatory breast disease that primarily affects premenopausal women, often in the postpartum period or after breastfeeding. Its nonspecific clinical and imaging presentation, frequent overlap with infectious and neoplastic conditions, and variable therapeutic response make both diagnosis and management challenging. This report aims to describe the clinical characteristics, diagnostic approach, and corticosteroid response in two histologically confirmed cases, highlighting differences in therapeutic outcomes and the relevance of individualized regimens. Both patients presented with chronic inflammatory breast lesions unresponsive to antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), requiring corticosteroid therapy for disease control. One case showed partial response with frequent relapses despite prolonged treatment, whereas the other achieved complete remission with a low-dose, tapered regimen and no recurrences. Comparative analysis and literature review suggest that disease extent and inflammatory phenotype significantly influence responsiveness, supporting early initiation of prednisone at 0.5-1 mg/kg/day with individualized tapering, and consideration of immunosuppressants in recurrent or steroid-dependent cases. Intralesional corticosteroids may be effective in localized disease, while surgery should be reserved for refractory presentations due to higher recurrence rates. These findings reinforce the role of systemic corticosteroids as first-line therapy for IGM while emphasizing the need for tailored treatment strategies and the generation of local evidence to optimize outcomes, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.